Hospital Variations in Time‐To‐Crisis‐Resolution Among Children and Adolescents With Sickle Cell Disease
Year: 2025
Type: article
Abstract: Analysis of the placebo cohort in the STArT trial shows that patient characteristics and hospital site strongly influence time-to-crisis-resolution and total opioid use in children and young adults with sickle cell disease, highlighting the need to account for these factors in the design of future clinical trials.
Source: American Journal of Hematology
DOI: 10.1002/ajh.70129
Authors: Chris A. Rees, Dunia Hatabah, Rawan Korman, Fahd Ahmad, Gladstone Airewele, Bolanle Akinsola, Noor Alzraikat, Nitya Bakshi, David C. Brousseau, Kathleen Brown, Andrew D. Campbell, T. Charles Casper, Todd P. Chang, Corrie E. Chumpitazi, Daniel Cohen, Keli D. Coleman, Andrea T. Cruz, Christopher Denton, Angela Ellison, Melanie E. Fields, Monica Harding, Sara Leibovich, Allison Remiker, Nidhi V. Singh, Alexis A. Thompson, Elliott Vichinsky, Anthony Villella, Bridget Wynn, Carlton Dampier, Claudia R. Morris
Institutions: Emory University, Children's Healthcare of Atlanta, Washington University in St. Louis, Baylor College of Medicine, Texas Children's Hospital, Yale University, Thomas Jefferson University, Children's National, George Washington University, University of Utah, University of Southern California, Children's Hospital Los Angeles, Duke University, Duke Medical Center, Nationwide Children's Hospital, Medical College of Wisconsin, Children's Hospital of Philadelphia, University of California, San Francisco, University of California San Francisco Medical Center, UCSF Benioff Children's Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G2566951180, G2810492374, G2849384411, G2869228400, 1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial), G4160209598, G4206347462, G4978979719, G5142404812, G6582056024, G7144940715, G7797997618, G78948565, G8180440518, G8253428667, Patient-Oriented Research in Arginine Deficiency Syndromes, 2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial, G991479106
OpenAlex ID: W4415924660